<DOC>
	<DOCNO>NCT01269216</DOCNO>
	<brief_summary>This open-label , randomized phase II study . Patients randomly assign either FL TS-1/irinotecan preoperative chemotherapy regimens stratification . Patients FL group treat bolus injection 5-FU 400 mg/m2/day LV 20 mg/m2/day 3 consecutive day every 4 week 2 cycle , patient TS-1/irinotecan treated irinotecan 40 mg/m2/day day 1 , 8 , 15 , 22 , 29 . TS-1 dose 35mg/m2 administer orally twice day meal day irradiation ( Monday-Friday ) concurrent radiotherapy .</brief_summary>
	<brief_title>A Study Neoadjuvant Chemoradiotherapy With 5-FU/Leucovorin ( FL ) vs. TS-1/Irinotecan Patients With Locally Advanced Rectal Cancer</brief_title>
	<detailed_description>This open-label , randomized phase II study . Patients randomly assign either FL TS-1/irinotecan preoperative chemotherapy regimens stratification . Patients FL group treat bolus injection 5-FU 400 mg/m2/day LV 20 mg/m2/day 3 consecutive day every 4 week 2 cycle , patient TS-1/irinotecan treated irinotecan 40 mg/m2/day day 1 , 8 , 15 , 22 , 29 . TS-1 dose 35mg/m2 administer orally twice day meal day irradiation ( Monday-Friday ) concurrent radiotherapy . Total 45-50.4 Gy radiation 25-28 fraction tumor drain lymph node deliver concurrently . Curative surgery ( especially total mesorectal excision consider 1st choice surgical procedure ) perform 4-8 week completion chemoradiotherapy . Postoperative chemotherapy regimen 5-FU plus leucovorin .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histologically confirm adenocarcinoma rectum AJCC/UICC pathologic stage cT34 cN plus Male female patient , 18 year age old Be ambulatory Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . No prior chemotherapy , radiotherapy immunotherapy Adequate major organ function follow : Hematopoietic function : ANC ( absolute neutrophil count ) 1,500/mm3 , Platelet 100,000/mm3 , Hepatic function : serum bilirubin &lt; 1.5 x ULN , AST/ALT level &lt; 2.5 x ULN , Renal function : serum creatinine &lt; 1.5 x ULN Ccr 50 ml/min Cockcroft formula Be willing able comply protocol duration study . Give write informed consent prior studyspecific screening procedure , understand patient right withdraw study time , without prejudice . Any histologic feature adenocarcinoma arise chronic inflammatory bowel disease Patients treat previous surgery , chemotherapy and/or radiotherapy Uncontrolled severe cardiovascular disease : New York Heart Association class III IV heart disease , Unstable angina myocardial infarction within past 6 month , History significant ventricular arrhythmia require medication antiarrhythmic significant conduction system abnormality . Serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy . Other malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix . Organ allograft require immunosuppressive therapy . Psychiatric disorder uncontrolled seizure would preclude compliance . Pregnant , nurse woman patient reproductive potential without contraception . Patients receive concomitant treatment drug interact 5FU irinotecan flucytosine , phenytoin , warfarin et al . Prior unanticipated severe reaction fluoropyrimidine therapy , know dihydropyrimidine dehydrogenase ( DPD ) deficiency . Known hypersensitivity component study medication . Received investigational drug agent within 4 week begin treatment study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>